Charles N. York II - May 1, 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Signature
/s/ Charles N. York II
Stock symbol
DAWN
Transactions as of
May 1, 2024
Transactions value $
-$1,081,191
Form type
4
Date filed
5/3/2024, 06:44 PM
Previous filing
Feb 20, 2024
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$933K -52.2K -18.79% $17.89 226K May 1, 2024 Direct F1, F2
transaction DAWN Common Stock Sale -$3.58K -200 -0.09% $17.90 225K May 2, 2024 Direct F1, F3
transaction DAWN Common Stock Sale -$144K -8.08K -3.58% $17.85 217K May 3, 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 6, 2023.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $17.955 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.